BIVI — BioVie Inc. Company Overview

Executive Summary

BioVie is a clinical-stage biopharmaceutical company (Nasdaq: BIVI) developing therapies for neurological/neurodegenerative disorders and advanced liver disease, with no approved products and no product revenue. Its fiscal year ends June 30; the most recent 10-K, filed August 13, 2026, covers the year ended June 30, 2026. The company's lead and most closely watched asset is bezisterim (NE3107), an oral small molecule that inhibits inflammation-driven insulin resistance via ERK and NFκB pathway modulation, in development for Parkinson's disease, Alzheimer's disease, and long COVID. In August 2026, BioVie reported positive Phase 2b SUNRISE-PD results (57 early-stage Parkinson's patients) meeting the primary endpoint with a statistically significant improvement in a composite neuroinflammation biomarker (p=0.0018), and as of September 2026 the company was actively engaging the FDA to define its Phase 3 Parkinson's program. Its second franchise, BIV201 (continuous-infusion terlipressin), targets ascites in liver cirrhosis and carries FDA Fast Track and Orphan Drug designations, with Phase 2 data showing a 53% reduction in ascites fluid during treatment. BioVie is small (13 full-time employees) and entirely dependent on trial outcomes and external financing/grant support, including a $13.1 million U.S. Department of Defense grant funding its long-COVID trial.

Core Business Model

BioVie is a pure clinical-stage drug developer: it funds preclinical and clinical development of small-molecule and biologic candidates in-house and through licensing/grant relationships, with the intent to either commercialize approved products directly or partner/out-license them to larger pharmaceutical companies. It has generated no product revenue to date. Government and non-dilutive funding (the $13.1 million DoD grant for the ADDRESS-LC long-COVID trial) plays a meaningful role in extending runway and validating specific programs, alongside conventional equity financing (including at-the-market and shelf offerings disclosed in periodic filings).

Business Segments

BioVie operates as a single clinical-stage biopharmaceutical entity but manages two distinct therapeutic programs that function as de facto segments:

1. Neurodegenerative/neuroinflammatory disease programs — bezisterim (NE3107) across Parkinson's disease, Alzheimer's disease, and long COVID.
2. Liver cirrhosis program — BIV201 (continuous-infusion terlipressin) for ascites.

Product Portfolio

• Bezisterim (NE3107) — Parkinson's disease: Phase 2b SUNRISE-PD (57 patients) met its primary pharmacodynamic endpoint (composite neuroinflammation biomarker, p=0.0018) with favorable secondary motor/non-motor signals; the company announced in September 2026 that it is advancing FDA engagement to define the Phase 3 development path.
• Bezisterim — Alzheimer's disease: A Phase 3 trial (NCT04669028) in mild-to-moderate AD faced significant site-level compliance/protocol-violation issues, forcing exclusion of patients from 15 sites and leaving the study underpowered; in the remaining 57-patient per-protocol population, bezisterim showed a descriptive signal suggestive of slowed cognitive decline, but this is not a clean positive Phase 3 result and will require further confirmatory work.
• Bezisterim — Long COVID (ADDRESS-LC): Phase 2 trial funded by a $13.1 million DoD grant; enrollment completed May 2026, with topline results expected in late summer 2026.
• BIV201 (continuous-infusion terlipressin) — liver cirrhosis/ascites: A novel room-temperature-stable (up to two years) liquid formulation; holds FDA Fast Track and Orphan Drug designations. Phase 2 data showed a 53% reduction in ascites fluid during treatment, sustained at 43% reduction three months post-treatment. The company is finalizing Phase 3 protocol design with FDA input.

Competitive Landscape

For bezisterim, BioVie does not name direct mechanism-specific competitors in its 10-K beyond acknowledging "numerous, well-established and well capitalized competitors" across biotechnology broadly; the practical competitive set includes the much larger Alzheimer's and Parkinson's pipelines at companies like Eisai/Biogen (lecanemab), Eli Lilly (donanemab), and various neuroinflammation-focused biotechs. For BIV201, the terlipressin competitive landscape is more concretely disclosed: Mallinckrodt Hospital Products holds an Orphan Drug designation (2004) for terlipressin in hepatorenal syndrome and received FDA approval for that indication in September 2022 (marketed as Terlivaz); PharmaIN Corporation holds a 2012 Orphan Drug designation for a terlipressin formulation; and Ferring Pharmaceuticals holds a 1986 Orphan Drug designation for terlipressin in bleeding esophageal varices. BioVie's differentiation is a continuous-infusion, room-temperature-stable formulation targeting ascites specifically rather than the acute hepatorenal syndrome indication Mallinckrodt has already captured.

Strategic Strengths & Risks

Strengths: Bezisterim's positive, statistically significant SUNRISE-PD Phase 2b readout is a genuine de-risking event for the Parkinson's program and gives BioVie leverage in FDA discussions on Phase 3 design. BIV201's Fast Track and Orphan Drug designations, plus a differentiated room-temperature-stable formulation, provide a defensible niche within the narrow terlipressin competitive set (versus Mallinckrodt, PharmaIN, Ferring). A substantial IP estate (12 issued U.S. patents plus 7 pending for bezisterim; multiple international patents for BIV201 across the U.S., China, Japan, Australia, India, Mexico, and Chile) supports exclusivity. Non-dilutive government funding (the DoD grant) reduces shareholder dilution for at least one major trial.

Risks: The Alzheimer's Phase 3 trial's site-compliance failures and underpowered per-protocol analysis are a significant setback that complicates the bezisterim story and raises execution-risk questions about trial site management. BioVie has no approved products, no revenue, and is entirely dependent on continued capital markets access and non-dilutive funding to reach commercial milestones. With only 13 full-time employees, the company has thin organizational bandwidth to run multiple concurrent late-stage programs (Parkinson's, long COVID, liver cirrhosis) simultaneously. Binary trial and regulatory-interaction outcomes (FDA's response on Phase 3 Parkinson's design, ADDRESS-LC topline data expected late summer 2026) represent material near-term catalysts and risks.

Financial Overview

BioVie is pre-revenue with no FDA-approved products, consistent with its clinical-stage status. Its fiscal year 2026 10-K (period ended June 30, 2026, filed August 13, 2026) reflects continued R&D-driven cash burn typical of a multi-program clinical biotech, funded through a combination of equity financings, at-the-market facilities, and non-dilutive government grant funding (including the $13.1 million DoD award for ADDRESS-LC). The company's addressable markets are sizeable on a patient-population basis: roughly 6 million Americans with Alzheimer's disease, approximately 1 million with Parkinson's disease, an estimated 20 million with long COVID symptoms, and roughly 116,000 annual U.S. hospital discharges for cirrhosis-related ascites, with BioVie characterizing the ascites market opportunity alone as exceeding $650 million.

Summary Conclusion

BioVie is a small, clinical-stage biopharmaceutical company with two credible, differentiated programs — bezisterim in Parkinson's disease (following a positive Phase 2b readout) and BIV201 in cirrhotic ascites (with Fast Track/Orphan Drug status and a narrow, well-characterized competitive set) — offset by a genuine setback in its Alzheimer's Phase 3 program due to trial-execution issues. With no revenue and continued dependence on external financing, the investment case rests heavily on the FDA's response to the Parkinson's Phase 3 design discussions and the ADDRESS-LC long-COVID data expected in late summer 2026, both of which are near-term, high-impact catalysts for a company of BioVie's size.